Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Sparx Therapeutics is expanding its operations into Yangzhou, China, with the imminent construction of a 1.2 million square foot facility for its commercial production.
This week’s announcement includes a step to the side for CMO Amit Rakhit, who will transition to the biotech’s advisory board.
Agenus, an immuno-oncology company based out of Lexington, Mass., has purchased a 120-acre plot of land near Genentech’s manufacturing facility in Vacaville, Cali.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Scorpion Therapeutics announced its new CEO Dr. Axel Hoos while Tenax Therapeutics named Christopher Giordano as its new chief executive.
Startups have passion and big, bold ideas. Pharma has the funds and human resources. Together, they can change the future of medicine.
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
Two life sciences companies from two very different areas of medicine announced launches today. Here’s a look.
This morning, multiple companies announced clinical and strategic collaborations to develop novel therapies and treatments for various diseases. Here are some of them.
Perseverance is the foundation of impactful scientific discoveries, and is a core value that Precision BioSciences’ newly-appointed chief medical officer, oncology giant Alan List, shares.